The report encapsulates a comprehensive overview of the network’s achievements, breakthroughs, and collaborations in the field of glycomics throughout the past year.
Within the report, readers will gain insight into the cutting-edge research and advancements made by GlycoNet, a collaborative effort involving scientists, researchers, and experts from academia, industry, and government institutions. It delves into the pioneering discoveries in glycobiology, highlighting the innovative applications and technologies that have emerged within the network.
Senator Paula Simons recently toured GlycoNet at the University of Alberta, exploring the realm of glycomics. The visit highlighted GlycoNet’s pivotal role in advancing glycomics and its transformative impact across One Health domains, underlined by discussions with GlycoNet’s CEO, Dr. Elizabeth Nanak.
The tour of cutting-edge labs showcased passionate researchers driving innovation in glycomics, and interactions with start-ups like 48Hour Discovery shed light on drug discovery advancements. This visit emphasized the value of such engagements, illustrating the shared commitment to a thriving future and the potential for collaborative efforts to elevate healthcare and nurture a diverse bioeconomy.
New compounds could open more opportunities for vital medical treatments, organ and tissue transplants, and reproductive medicine.
GlycoNet scientists are expanding our knowledge of sugars to engineer new health solutions.
Over 150 top researchers, industry experts, and emerging talent in glycomics recently gathered in Edmonton, Alberta to discuss advancements and the latest trends in glycomics.
GlycoNet and its Integrated Services advance glycomics research and innovation towards new solutions.
Five glycomics projects have been awarded funding to develop new tools, diagnostics and therapeutics to improve health for Canadians.
A significant gathering of researchers, industry experts, and rising stars in glycomics recently took place in Edmonton, Alberta with the Honourable Randy Boissonnault, focusing on advancements and current trends in the field.
Finding that the skin of people with scleroderma makes a unique sugar, GlycoNet researcher Lisa Willis is developing a way to better identify those at high risk of disease progression.
PlantForm Corporation has teamed up with a University of British Columbia research group led by Dr. Joerg Bohlmann to develop a novel plant-based treatment option for Type-2 diabetes and obesity, with support from GlycoNet.